{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(2)"],"submitter":["Udovicich C"],"pubmed_abstract":["<h4>Importance</h4>Stereotactic body radiotherapy (SBRT) and high-dose-rate brachytherapy monotherapy (HDR-BT) are options for intermediate-risk prostate cancer. However, no prospective evidence is available to compare these modalities.<h4>Objective</h4>To compare the biochemical failure (BCF), late patient-reported quality of life (PR-QoL), and acute and late adverse events (AEs) associated with SBRT and HDR-BT using prospective data.<h4>Data sources</h4>This was an individual patient data post hoc pooled analysis of 5 prospective trials with recruitment from 2010 to 2018. Statistical analyses were performed in September 2024.<h4>Study selection</h4>This was a post hoc analysis of these 5 sprospective trials. Eligibility criteria comprised men with intermediate-risk prostate cancer underg"],"journal":["JAMA network open"],"pagination":["e260146"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12936880"],"repository":["biostudies-literature"],"pubmed_title":["SBRT vs HDR Brachytherapy for Intermediate-Risk Prostate Cancer."],"pmcid":["PMC12936880"],"pubmed_authors":["Ong WL","McGuffin M","Loblaw A","Chu W","Detsky J","Morton G","Kulasingham-Poon M","Cheung P","Udovicich C","Liu S","Hudson JM","Zhang L","Chung H","Tseng CL","Kennedy T","Deabreu A","Vesprini D","Ravi A","Davidson M","Mamedov A","Helou J"],"additional_accession":[]},"is_claimable":false,"name":"SBRT vs HDR Brachytherapy for Intermediate-Risk Prostate Cancer.","description":"<h4>Importance</h4>Stereotactic body radiotherapy (SBRT) and high-dose-rate brachytherapy monotherapy (HDR-BT) are options for intermediate-risk prostate cancer. However, no prospective evidence is available to compare these modalities.<h4>Objective</h4>To compare the biochemical failure (BCF), late patient-reported quality of life (PR-QoL), and acute and late adverse events (AEs) associated with SBRT and HDR-BT using prospective data.<h4>Data sources</h4>This was an individual patient data post hoc pooled analysis of 5 prospective trials with recruitment from 2010 to 2018. Statistical analyses were performed in September 2024.<h4>Study selection</h4>This was a post hoc analysis of these 5 sprospective trials. Eligibility criteria comprised men with intermediate-risk prostate cancer underg","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-16T22:07:50.405Z","creation":"2026-07-11T03:11:51.065Z"},"accession":"S-EPMC12936880","cross_references":{"pubmed":["41739470"],"doi":["10.1001/jamanetworkopen.2026.0146"]}}